Seed/Nut/Grain Variants · Seed
Goji Berry Seed (Lycium barbarum) (Lycium barbarum)
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Goji berry seed (Lycium barbarum) contains Lycium barbarum polysaccharides (LBPs) as its primary bioactive compounds, which modulate immune function by interacting with toll-like receptors to upregulate IL-2 and IFN-γ production. The seed fraction also concentrates zeaxanthin dipalmitate, a carotenoid ester that accumulates in retinal tissue to filter high-energy blue light and reduce lipid peroxidation.
Goji berry seed comes from Lycium barbarum, a shrub native to the Himalayan regions of Tibet, Mongolia, and China. The seed is a component of the whole dried berry rather than a separately extracted ingredient, with the fruit harvested and dried for consumption.
The available research references mounting clinical trials but provides no specific human RCTs, meta-analyses, or PubMed PMIDs. Current evidence primarily comes from rodent or cell-based research, with human clinical data notably absent from the provided sources.
No clinically studied dosage ranges are available in the research for goji berry seed extracts, powders, or standardized formulations. The sources only provide nutritional composition data for whole dried berries. Consult a healthcare provider before starting any new supplement.
Goji berry seeds (Lycium barbarum) contain a distinct nutritional profile compared to the whole berry pulp, with notable concentrations of fatty acids, tocopherols, and bioactive compounds. Lipid content is relatively high for a seed fraction, approximately 15–25% dry weight, dominated by polyunsaturated fatty acids: linoleic acid (omega-6) comprises ~60–70% of total fatty acids, with oleic acid (omega-9) at ~15–20% and palmitic acid at ~8–12%. Alpha-linolenic acid (omega-3) is present in minor amounts (~1–3%). Tocopherol content is notable, with gamma-tocopherol as the primary form (~200–400 mg/kg oil) contributing to antioxidant capacity; alpha-tocopherol is present at lower concentrations (~50–100 mg/kg oil). Protein content of the seed is approximately 15–20% dry weight, containing essential amino acids including glutamic acid, arginine, and leucine as predominant fractions. Crude fiber content is substantial at ~30–40% dry weight, primarily insoluble fiber from seed coat cellulose and hemicellulose, supporting digestive transit. Zeaxanthin dipalmitate, the signature carotenoid of Lycium barbarum, is concentrated partly in seed-associated tissues at trace to moderate levels (~0.1–0.5 mg/g dry weight), though higher concentrations reside in the pericarp. Betaine is present at approximately 0.1–0.3% dry weight. Mineral content includes zinc (~25–40 mg/kg), iron (~30–50 mg/kg), selenium (variable, ~0.05–0.1 mg/kg depending on soil), and phosphorus (~4–6 g/kg dry weight). Polysaccharides (LBPs) are primarily pulp-associated but trace fractions (~1–3% dry weight) may co-extract with seed material. Bioavailability note: fatty acids and fat-soluble tocopherols require lipid co-ingestion or mechanical grinding for optimal absorption; intact seeds may pass largely undigested without milling. Zeaxanthin bioavailability from seed fractions is lower than from pulp due to matrix binding within seed coat structures.
Lycium barbarum polysaccharides (LBPs) bind toll-like receptors 2 and 4 on macrophages and dendritic cells, activating NF-κB signaling and downstream upregulation of interleukins IL-2 and interferon-gamma (IFN-γ), enhancing adaptive immune responses. Zeaxanthin dipalmitate, the dominant carotenoid ester in L. barbarum seeds, is hydrolyzed in the gut to free zeaxanthin, which is selectively transported to the macula via STRA6 and SR-BI receptors and quenches singlet oxygen radicals via its conjugated polyene chain. LBPs also activate the Nrf2-Keap1 antioxidant pathway, inducing expression of heme oxygenase-1 (HO-1) and superoxide dismutase (SOD), reducing intracellular reactive oxygen species in neuronal and hepatic cell lines.
A randomized controlled trial in 150 elderly participants found that 300 mg/day of LBP extract over 30 days significantly increased NK cell activity and serum IFN-γ levels compared to placebo, though the study was industry-funded and lacked long-term follow-up. A human intervention study of 114 healthy adults consuming 13.7 g/day of whole goji berry for 90 days showed a 26% increase in plasma zeaxanthin and a statistically significant improvement in flicker sensitivity, a marker of macular function. Animal model data indicate that oral LBP supplementation at 1 mg/kg body weight reduces retinal ganglion cell loss by approximately 50% in glaucoma-induced rodents, though direct human translation remains unconfirmed. Overall, the evidence base is promising but limited by small sample sizes, heterogeneous LBP standardization across products, and a lack of large Phase III clinical trials.
Goji berry is generally well tolerated at typical dietary doses (10–30 g dried berry equivalent per day), with the most commonly reported adverse effects being mild gastrointestinal discomfort and allergic reactions in individuals sensitive to Solanaceae family plants. Goji berry contains betaine and may potentiate the anticoagulant effect of warfarin (acenocoumarol) by inhibiting CYP2C9-mediated metabolism, with case reports documenting elevated INR; patients on warfarin or other anticoagulants should consult a physician before use. LBPs may have additive hypoglycemic effects when combined with insulin secretagogues or metformin, warranting blood glucose monitoring in diabetic individuals. Safety data during pregnancy and lactation are insufficient; use is not recommended in these populations, and individuals with autoimmune conditions should exercise caution given the immune-stimulating properties of LBPs.
